vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $196.9M, roughly 1.7× Pacira BioSciences, Inc.). On growth, PRA GROUP INC posted the faster year-over-year revenue change (13.7% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-90.4M). Over the past eight quarters, PRA GROUP INC's revenue compounded faster (14.2% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
PCRX vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $333.4M |
| Net Profit | — | $56.5M |
| Gross Margin | 79.5% | — |
| Operating Margin | 1.2% | 37.7% |
| Net Margin | — | 17.0% |
| Revenue YoY | 5.1% | 13.7% |
| Net Profit YoY | — | 206.3% |
| EPS (diluted) | $0.05 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $333.4M | ||
| Q3 25 | $179.5M | $311.1M | ||
| Q2 25 | $181.1M | $287.7M | ||
| Q1 25 | $168.9M | $269.6M | ||
| Q4 24 | $187.3M | $293.2M | ||
| Q3 24 | $168.6M | $281.5M | ||
| Q2 24 | $178.0M | $284.2M | ||
| Q1 24 | $167.1M | $255.6M |
| Q4 25 | — | $56.5M | ||
| Q3 25 | $5.4M | $-407.7M | ||
| Q2 25 | $-4.8M | $42.4M | ||
| Q1 25 | $4.8M | $3.7M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $-143.5M | $27.2M | ||
| Q2 24 | $18.9M | $21.5M | ||
| Q1 24 | $9.0M | $3.5M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | 37.7% | ||
| Q3 25 | 3.5% | -101.4% | ||
| Q2 25 | 4.7% | 29.6% | ||
| Q1 25 | 1.2% | 27.7% | ||
| Q4 24 | 13.2% | 32.1% | ||
| Q3 24 | -82.8% | 32.0% | ||
| Q2 24 | 15.9% | 31.4% | ||
| Q1 24 | 7.9% | 26.0% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | 3.0% | -131.0% | ||
| Q2 25 | -2.7% | 14.7% | ||
| Q1 25 | 2.8% | 1.4% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -85.1% | 9.6% | ||
| Q2 24 | 10.6% | 7.6% | ||
| Q1 24 | 5.4% | 1.4% |
| Q4 25 | $0.05 | $1.47 | ||
| Q3 25 | $0.12 | $-10.43 | ||
| Q2 25 | $-0.11 | $1.08 | ||
| Q1 25 | $0.10 | $0.09 | ||
| Q4 24 | $0.38 | $0.47 | ||
| Q3 24 | $-3.11 | $0.69 | ||
| Q2 24 | $0.39 | $0.54 | ||
| Q1 24 | $0.19 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $104.4M |
| Total DebtLower is stronger | $372.2M | — |
| Stockholders' EquityBook value | $693.1M | $979.9M |
| Total Assets | $1.3B | $5.1B |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $104.4M | ||
| Q3 25 | $246.3M | $107.5M | ||
| Q2 25 | $445.9M | $131.6M | ||
| Q1 25 | $493.6M | $128.7M | ||
| Q4 24 | $484.6M | $105.9M | ||
| Q3 24 | $453.8M | $141.1M | ||
| Q2 24 | $404.2M | $118.9M | ||
| Q1 24 | $325.9M | $108.1M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $979.9M | ||
| Q3 25 | $727.2M | $928.5M | ||
| Q2 25 | $757.8M | $1.3B | ||
| Q1 25 | $798.5M | $1.2B | ||
| Q4 24 | $778.3M | $1.1B | ||
| Q3 24 | $749.6M | $1.2B | ||
| Q2 24 | $879.3M | $1.1B | ||
| Q1 24 | $892.2M | $1.1B |
| Q4 25 | $1.3B | $5.1B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.5B | $5.4B | ||
| Q1 25 | $1.6B | $5.1B | ||
| Q4 24 | $1.6B | $4.9B | ||
| Q3 24 | $1.5B | $4.9B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.6B | $4.5B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $-85.5M |
| Free Cash FlowOCF − Capex | $43.5M | $-90.4M |
| FCF MarginFCF / Revenue | 22.1% | -27.1% |
| Capex IntensityCapex / Revenue | 0.1% | 1.4% |
| Cash ConversionOCF / Net Profit | — | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $-85.5M | ||
| Q3 25 | $60.8M | $-10.1M | ||
| Q2 25 | $12.0M | $-12.9M | ||
| Q1 25 | $35.5M | $-52.6M | ||
| Q4 24 | $33.1M | $-94.6M | ||
| Q3 24 | $53.9M | $-35.0M | ||
| Q2 24 | $53.2M | $-29.5M | ||
| Q1 24 | $49.1M | $-73.0M |
| Q4 25 | $43.5M | $-90.4M | ||
| Q3 25 | $57.0M | $-11.3M | ||
| Q2 25 | $9.3M | $-14.2M | ||
| Q1 25 | $26.9M | $-53.5M | ||
| Q4 24 | $31.0M | $-98.6M | ||
| Q3 24 | $49.8M | $-36.1M | ||
| Q2 24 | $51.6M | $-30.8M | ||
| Q1 24 | $46.3M | $-73.5M |
| Q4 25 | 22.1% | -27.1% | ||
| Q3 25 | 31.7% | -3.6% | ||
| Q2 25 | 5.1% | -4.9% | ||
| Q1 25 | 15.9% | -19.8% | ||
| Q4 24 | 16.6% | -33.6% | ||
| Q3 24 | 29.6% | -12.8% | ||
| Q2 24 | 29.0% | -10.8% | ||
| Q1 24 | 27.7% | -28.8% |
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 2.2% | 0.4% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 5.1% | 0.3% | ||
| Q4 24 | 1.1% | 1.4% | ||
| Q3 24 | 2.4% | 0.4% | ||
| Q2 24 | 0.9% | 0.5% | ||
| Q1 24 | 1.7% | 0.2% |
| Q4 25 | — | -1.51× | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | 7.37× | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | 2.82× | -1.37× | ||
| Q1 24 | 5.47× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
